Skip to main content

Advertisement

Table 2 Details of pre- and study medication.

From: Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?

Age 6-12 years N = 583 13-18 years N = 239 All patients N = 822 U-test2 Chi2-test3
Reason for starting OROS MPH, n (%)1     
   N 142 (100.00) 82 (100.00) 224 (100.00) p < 0.0903
   insufficient effectiveness 92 (64.79) 63 (76.83) 155 (69.20)  
   adverse events 5 (3.52) 4 (4.88) 9 (4.02)  
   combination of both 45 (31.69) 15 (18.29) 60 (26.79)  
Dose of OROS MPH     
   starting dose (mg/day) 29.05 ± 11.71 37.58 ± 15.62 31.53 ± 13.52 p < 0.0012
   minimum, median, maximum 18, 36, 72 18, 36, 108 18, 36, 108  
   last visit 32.82 ± 12.68 41.95 ± 15.07 35.47 ± 14.04 p < 0.0012
   minimum, median, maximum 18, 36, 72 18, 36, 108 18, 36, 108  
   Difference (mean ± SD) 3.77 ± 9.03 4.37 ± 10.43 3.94 ± 9.46 p = 0.5792
   Wilcoxon p-value < 0.0001 < 0.0001 < 0.0001  
Dose of OROS MPH (mg/day/kg BW) N = 527 4 N = 223 4 N = 750 4  
   starting dose (mg/day/kg BW) 0.90 ± 0.41 0.73 ± 0.39 0.85 ± 0.41 p < 0.0012
   minimum, median, maximum 0.30,0.82,3.13 0.20,0.66,2.77 0.20,0.78,3.13  
   last visit 1.03 ± 0.45 0.82 ± 0.37 0.97 ± 0.44 p < 0.0012
   minimum, median, maximum 0.29,0.95,3.13 0.20,0.72,2.32 0.20,0.88,3.13  
   Difference (mean ± SD) 0.13 ± 0.32 0.08 ± 0.20 0.11 ± 0.29 p = 0.6652
   Wilcoxon p-value < 0.0001 < 0.0001 < 0.0001  
Days of treatment with OROS MPH 82.90 ± 30.32 87.36 ± 27.15 84.20 ± 29.49 p = 0.0122
Days of observation 85.97 ± 29.35 89.05 ± 26.10 86.87 ± 28.46 p = 0.0462
Number (%) of patients with at least one additional application of IR MPH between study start and study end     
   yes 180 (30.87) 68 (28.45) 248 (30.17) p = 0.5463
   no 403 (69.13) 171 (71.55) 574 (69.83)  
  1. 1 Data only available for patients (n = 224) from the GER-CON-2 study
  2. 2,3 p-values from the corresponding test between age groups: 6-12 years and 13-18 years
  3. 4 Determined only in patients with bodyweight documented at first and last visit
  4. Abbreviations: BW = bodyweight; IR = immediate-release; MPH = methylphenidate.